24/7 Market News Snapshot 30 December, 2024 – Microbot Medical, Inc. Common Stock (NASDAQ:MBOT)

December 30, 2024

DENVER, Colo., 30 December, 2024 (247marketnews.com) – (NASDAQ:MBOT) are discussed in this article.
Microbot Medical, Inc. is experiencing a notable upswing in its market performance as it gears up for significant advancements. Currently trading at $1.242, the stock has risen by 11.89% from the previous close of $1.110, reflecting robust buying interest and encouraging investor sentiment. The trading volume has reached 769.46K, suggesting an active market engagement that may indicate a forthcoming breakout. Investors are advised to keep an eye on critical resistance levels around $1.30, while support stands at $1.10, as these factors will be instrumental in determining the stock’s trajectory.

In conjunction with its market performance, Microbot Medical has accomplished key milestones in the development of its LIBERTY® Endovascular Robotic System, anticipated for commercial launch in 2025. The company recently completed a vital FDA 510(k) submission, marking a significant step towards regulatory approval. CEO Harel Gadot expressed optimism about the company’s direction, attributing progress to the dedicated efforts of the team and the support from stakeholders.

This past year has seen Microbot reach critical achievements, including obtaining Investigational Drug Exemption (IDE) approval from the FDA and finalizing the ACCESS-PVI pivotal human clinical trial across three esteemed medical centers. These developments have provided essential insights to enhance the LIBERTY® system further.

To prepare for commercialization, Microbot has set up a solid pre-commercial infrastructure, achieving ISO 13485 certification and beginning inventory buildup. The company has also fostered strategic partnerships, notably with Corewell Health for telesurgery and Emory University for robotics advancement, bolstering its growth potential.

With plans to launch LIBERTY® in the U.S. by Q2 2025 and seek international regulatory approvals, Microbot Medical is strategically positioned to transform patient care through its cutting-edge endovascular robotic systems.

Related news for (MBOT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.